CAL-101 Chemical Properties

Melting point:

250-252oC

Boiling point:

733.4±70.0 °C(Predicted)

Density 

1.47

storage temp. 

-20°C

solubility 

Soluble in DMSO (>25 mg/ml)

form 

White solid.

pka

10.00±0.10(Predicted)

color 

White

Stability:

Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 2 months.

InChIKey

IFSDAJWBUCMOAH-HNNXBMFYSA-N

SMILES

N1C2=C(C(F)=CC=C2)C(=O)N(C2=CC=CC=C2)C=1[C@@H](NC1=C2C(=NC=N1)NC=N2)CC

Safety Information

Safety Statements 

V

HS Code 

29399990

Hazardous Substances Data

870281-82-6(Hazardous Substances Data)

CAL-101 Usage And Synthesis

Description

Idelalisib (CAS 870281-82-6) is a potent (IC50 = 2.5nM) and selective (IC50’s: PI3Ka = 820nM, PI3Kb = 565nM, PI3Kg = 89nM) PI3Kd inhibitor.1,2 Useful clinical agent for the treatment of various blood cancers. Idelalisib attenuates regulatory T cells (Treg) but not conventional T cells (Tconv) resulting in a significant increase in tumor-infiltrating antigen-specific CD8 T cells in a murine lung cancer model.3 Conversely, systemic PI3Kd inactivation antagonized anti-CTLA-4 and anti-PD-L1 treatment.4 Others have found that Idelalisib minimally influenced rituximab- and obinutuzumab-mediated Ab-dependent cellular cytotoxicity in human lymphoma cells.5

Uses

CAL-101 is a PI3K/mTOR pathway inhibitor used in the treatment of myeloid leukemia through sensitizing the cells to combatting drugs. Potent PI3K-p110-delta inhibitor.

Definition

ChEBI: A member of the class of quinazolines that is 5-fluoro-3-phenylquinazolin-4-one in which the hydrogen at position 2 is replaced by a (1S)-1-(3H-purin-6-ylamino)propyl group. used for for the treatment of refractory indol nt non-Hodgkin's lymphoma and relapsed chronic lymphocytic leukemia.

in vitro

CAL-101 (Idelalisib) is a highly selective and potent p110δ inhibitor (EC50=8 nM). Greater selectivity (400- to 4000-fold) is seen against related kinases C2β, hVPS34, DNA-PK, and mTOR, whereas no activity is observed against a panel of 402 diverse kinases at 10 μM. CAL-101 reduces PDGF-induced pAkt by only 25% at 10 μM. Idelalisib (CAL-101) inhibits LPA-induced pAkt with an EC50 of 1.9 μM. Idelalisib (CAL-101) blocks Fc?RI p110δ-mediated CD63 expression with an EC50 of 8 nM, whereas formyl-methionyl-leucyl-phenylalanine activation of p110γ is inhibited with an EC50 of 3 μM. Thus, CAL-101 has 240- to 2500-fold selectivity in cell-based assays for p110δ over the other class I PI3K isoforms. CAL-101Idelalisib (CAL-101)-induced apoptosis of chronic lymphocytic leukemia (CLL) cells is significant compared with vehicle treatment alone (P<0.001). Idelalisib (CAL-101) induces selective cytotoxicity in CLL cells independent of IgVH mutational status or interphase cytogenetics.

in vivo

A significant reduction is observed in the CD11b+Ly6G+ neutrophils from brain homogenates of bothp110δD910A/D910A mice and Idelalisib (CAL-101) (40 mg/kg, i.v.) post-treated mice.

target

p110δ

storage

Store at -20°C

References

[1] SARAH E M HERMAN. Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.[J]. Blood, 2010: 2078-2088. DOI:10.1182/blood-2010-02-271171
[2] BRIAN J LANNUTTI. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.[J]. Blood, 2011: 591-594. DOI:10.1182/blood-2010-03-275305
[3] SHAMIM AHMAD. Differential PI3Kδ Signaling in CD4+ T-cell Subsets Enables Selective Targeting of T Regulatory Cells to Enhance Cancer Immunotherapy.[J]. Cancer research, 2017, 77 8 1: 1892-1904. DOI:10.1158/0008-5472.can-16-1839
[4] EE LYN LIM. Phosphoinositide 3-kinase δ inhibition promotes antitumor responses but antagonizes checkpoint inhibitors.[J]. ACS Applied Nano Materials, 2018. DOI:10.1172/jci.insight.120626
[5] ADAM PALAZZO. The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo.[J]. ACS Applied Electronic Materials, 2018: 2304-2312. DOI:10.4049/jimmunol.1700323

CAL-101(870281-82-6)Related Product Information

• ARRY-334543
• Dovitinib
• 2-Amino-6-fluorobenzoic acid
• (S)-2-(1-aMinopropyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
• BOC-ABU-OH
• (S)-tert-butyl (1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)carbaMate
• 2-Fluoro-6-nitro-N-phenylbenzamide
• Everolimus
• Bortezomib
• BKM120 (NVP-BKM120, Buparlisib)
• Pictilisib
• IPI 145
• Ibrutinib
• Selumetinib Sulfate
• Savolitinib
• CO-1686
• Momelotinib
• 790299-79-5